Stay updated on Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.

Latest updates to the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now presents the completed Phase 2 AML study record, including its treatment approach, participant criteria, outcomes, investigators, results-related publications, and study documents, instead of an access error.SummaryDifference48%

- Check15 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH banner announces a terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 on the error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer’s displayed ClinicalTrials.gov revision changes from v3.7.0 to v3.7.1 on a 403 Forbidden page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous detailed study content with a minimal error page that includes a Home link and a revision notice.SummaryDifference18%

Stay in the know with updates to Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.